TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31124721

Group type: EXPERIMENTAL
Intervention: Adequately Controlled (AC) hypoparathyroidism
Number of subjects: 614

Group type: COMPARATOR
Intervention: Not Adequately Controlled (NAC) hypoparathyroidism
Number of subjects: 614
Study: 28810284

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid therapy (initial dose of 80 mg prednisolone for 2 weeks, tapered over 3 to 4 months)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 3
Study: 25724322

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention comprising twice-weekly exercise classes of one hour duration for 4 months, including aerobic exercise at moderate intensity and resistance exercise using weight vests, weight belts, and dumbbells.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unsupervised, independent exercise following the supervised intervention.
Number of subjects: 0
Study: 23543804

Group type: EXPERIMENTAL
Intervention: NSF-3 (one tablet at bedtime for two weeks)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Zolpidem (one 10 mg tablet at bedtime for two weeks)
Number of subjects: 91
Study: 21903982

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (target international normalized ratio 2 to 3)
Number of subjects: 1936

Group type: COMPARATOR
Intervention: Aspirin (325 mg) plus fixed, low-dose warfarin
Number of subjects: 1936
Study: 19562573

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 883
Study: 17097957

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) at 0.15 mg/kg/d
Number of subjects: 26
Study: 15337012

Group type: EXPERIMENTAL
Intervention: Excimer TMLR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Maximal medication (Control)
Number of subjects: 30
Study: 10891905

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Self-rated health (according to the first question of the SF-36)
Number of subjects: 97
Study: 8826889

Group type: EXPERIMENTAL
Intervention: rh alpha‐2b‐interferon (IFN) at a dose of 3 mU three times per week, given concurrently with VAD (VIC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: rh alpha‐2b‐interferon (IFN) at a dose of 3 mU three times per week, given as maintenance after completion of VAD (VIF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: VAD alone (historic control group)
Number of subjects: 72
Study: 1533166

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with continuous high TEA using 0.125% bupivacaine plus sufentanil (0.05 mL/cm body length/hr)
Number of subjects: 54

Group type: COMPARATOR
Intervention: General anesthesia (GA) with IV administration of nicomorphine (0.1 mg/kg every 6 hours)
Number of subjects: 54
Study: 3909977

Group type: EXPERIMENTAL
Intervention: Ethyl clofibrate (100 mg/kg, single oral dose between 24th and 48th hour of life)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 30255449

Group type: EXPERIMENTAL
Intervention: PBMT/magnetic field
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 21
Study: 28514601

Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg subcutaneously every 4 weeks for 52 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 26289355

Group type: EXPERIMENTAL
Intervention: 5 mg MAS‐XR
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 10 mg MAS‐XR
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 24121755

Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine
Number of subjects: 244

Group type: COMPARATOR
Intervention: tenofovir-DF/emtricitabine with efavirenz or atazanavir/ritonavir
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: time-updated values of IL-6, sTNFR-I and II, and sICAM-1
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: time-updated tumor necrosis factor α
Number of subjects: 244
Study: 23073140

Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate (1 mg - 100 mg single oral doses)
Number of subjects: 33
Study: 19038525

Group type: EXPERIMENTAL
Intervention: Individual Drug Counseling (IDC) + Group Drug Counseling (GDC) for 3 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC) alone for 3 months
Number of subjects: 41
Study: 17235504

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg subcutaneously after R-CHOP-14
Number of subjects: 10
Study: 15387326

Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (14, 28, or 56 g) twice daily for 7 days
Number of subjects: 9
Study: 12044300

Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐n1 [INS] (two tablets of 200 IU each, given sublingually once daily for eight months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐n1 [INS]
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10350219

Group type: EXPERIMENTAL
Intervention: CAMP recruitment strategies
Number of subjects: 1041
Study: 8983878

Group type: EXPERIMENTAL
Intervention: Peptide diet or oral prednisolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study: 1661630

Group type: EXPERIMENTAL
Intervention: otilonium bromide (OB) 40mg tid and normal diet (10‐15 g of fibers)
Number of subjects: 114

Group type: COMPARATOR
Intervention: high content of roughage diet (20 g of fibers) and 10 g of bran
Number of subjects: 114
Study: 6806486

Group type: EXPERIMENTAL
Intervention: Extended field megavoltage irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed androgen ablation
Number of subjects: 0
Study: 4076325

Group type: EXPERIMENTAL
Intervention: Verapamil (up to 120 mg t.i.d.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29264689

Group type: EXPERIMENTAL
Intervention: Morning (AM) administration of gonadotropins (uFSH and hMG)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Evening (PM) administration of gonadotropins (uFSH and hMG)
Number of subjects: 127
Study: 26863355

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 24169019

Group type: EXPERIMENTAL
Intervention: Intraprocedural thrombotic events (IPTEs)
Number of subjects: 3163
Study: 22446490

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20811348

Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of AZD3480 (10- and 50-fold higher exposures than a 20-mg dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of AZD3480 and 20-mg dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of AZD3480
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD3480
Number of subjects: 0
Study: 18985291

Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessed by the Trail-Making Test B at the onset of long-term treatment
Number of subjects: 125

Group type: COMPARATOR
Intervention: Initial clinical status
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Combination of neuropsychological and psychopathological variables
Number of subjects: 125
Study: 16162695

Group type: EXPERIMENTAL
Intervention: Regular albuterol nebulizations every 4 hours
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ad-lib albuterol nebulizations (saline solution nebulizations every 4 hours)
Number of subjects: 62
Study: 12631003

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 40
Study: 10694618

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.5 microg. kg(‐1). min(‐1))
Number of subjects: 30
Study: 8654326

Group type: EXPERIMENTAL
Intervention: Method A (extensive quantitative food frequency questionnaire)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Method B (novel shorter quantitative food frequency questionnaire with a 14 day food record)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Method B
Number of subjects: 241
Study: 1476278

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingual) + 100 mg oral hydroxyzine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (100 mg oral hydroxyzine)
Number of subjects: 60
Study: 6097521

Group type: EXPERIMENTAL
Intervention: Clonidine (2 x 0.05 mg/day) and low-dose conjugated estrogens (0.6 mg/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Higher dosage estrogens (1.25 mg/day)
Number of subjects: 83
Study: 31246237

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 652
Study: 29306517

Group type: EXPERIMENTAL
Intervention: Study A participants (younger; preserved eGFR)
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Study B participants (older; reduced eGFR)
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Study A participants with prolonged stable eGFRs
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Study B participants with stable eGFRs
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Nonprogressors in both studies
Number of subjects: 929
Study: 27048170

Group type: EXPERIMENTAL
Intervention: BAN2401 (0.1 mg/kg to 10 mg/kg biweekly for four months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAN2401
Number of subjects: 0
Study: 25194077

Group type: EXPERIMENTAL
Intervention: Diode laser ablation of prostate
Number of subjects: 36

Group type: COMPARATOR
Intervention: pTURP
Number of subjects: 36
Study: 22794216

Group type: EXPERIMENTAL
Intervention: 10 mL of 17% EDTA for 10 minutes + 10 mL of 1% NaOCl for 1 minute
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 mL of 5% EDTA for 10 minutes + 10 mL of 1% NaOCl for 1 minute
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 mL of 17% EDTA for 1 minute + 10 mL of 1% NaOCl for 1 minute
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 mL of 5% EDTA for 1 minute + 10 mL of 1% NaOCl for 1 minute
Number of subjects: 48

Group type: COMPARATOR
Intervention: 10 mL distilled water for 10 minutes
Number of subjects: 48
Study: 18760492

Group type: EXPERIMENTAL
Intervention: Erythropoietin administration
Number of subjects: 0
Study: 17699836

Group type: EXPERIMENTAL
Intervention: DTPa mixed with Hib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTPa and Hib coadministered
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed DTPa-based and Hib vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed DTPw-based and Hib vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTPa-based/Hib combination vaccines
Number of subjects: 0
Study: 16270845

Group type: EXPERIMENTAL
Intervention: CWT with enhanced incentives (n = 11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: CWT (n = 8)
Number of subjects: 19
Study: 12047324

Group type: COMPARATOR
Intervention: LAM group (30 mg of lansoprazole once daily, 500 mg of amoxicillin and 250 mg of metronidazole thrice daily for 2 weeks)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: LAMP group (same as LAM group plus 18,000 tyrosine units of pronase thrice daily for 2 weeks)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pronase (used in LAMP group)
Number of subjects: 135
Study: 9614676

Group type: EXPERIMENTAL
Intervention: Cold meal (4 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Room temperature meal (37 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hot meal (55 degrees C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison between 37 degrees C and 55 degrees C meals
Number of subjects: 10
Study: 7532501

Group type: EXPERIMENTAL
Intervention: Palliative care home support team (immediate service)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group (service after one month)
Number of subjects: 0
Study: 2644331

Group type: EXPERIMENTAL
Intervention: Poor diet high in sugar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Good diet without sugar
Number of subjects: 0
Study: 773735

Group type: EXPERIMENTAL
Intervention: Loperamide HCl
Number of subjects: 27
Study: 30697914

Group type: EXPERIMENTAL
Intervention: Routine physiotherapy with cupping therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 56
Study: 28003221

Group type: EXPERIMENTAL
Intervention: Longitudinal strain in anterior myocardial wall
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Longitudinal strain in lateral myocardial wall
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Longitudinal strain in inferior myocardial wall
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Longitudinal strain in septal myocardial wall
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Anterior longitudinal strain as a predictor of VT/VF
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Inferior longitudinal strain as a predictor of VT/VF
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Myocardial function in inferior wall including B-type natriuretic peptide
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Strain from inferior myocardial wall for predicting VT/VF
Number of subjects: 1064
Study: 26448178

Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg twice daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sunitinib (50 mg once daily for 4 weeks on treatment; 2 weeks off)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 96
Study: 24271647

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg) for 14 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 19
Study: 21169716

Group type: EXPERIMENTAL
Intervention: Balance training for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 12
Study: 19751559

Group type: EXPERIMENTAL
Intervention: Preemptive anti-Candida treatment based on corrected colonization index (CCI) when CCI >= 0.4 and evidence of sepsis; treatment not given when CCI < 0.4, but given if the patient's condition worsened.
Number of subjects: 110
Study: 17225720

Group type: EXPERIMENTAL
Intervention: Topical 0.05% fluticasone propionate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical 0.03% tacrolimus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Complementary fusidic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fusidic acid treatment
Number of subjects: 60
Study: 15554580

Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2DG)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 12003253

Group type: EXPERIMENTAL
Intervention: Chronic low-dose transdermal nicotine
Number of subjects: 0
Study: 9152688

Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 50
Study: 7953879

Group type: EXPERIMENTAL
Intervention: Magnetic application (800-1299 gauss)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nonmagnetic application
Number of subjects: 23
Study: 3828583

Group type: EXPERIMENTAL
Intervention: Portable masker
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo apparatus
Number of subjects: 21
Study: 29048234

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Parent Education Program (PEP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Parent Education Program (PEP-R)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Parent Training (PT-R)
Number of subjects: 180
Study: 26859064

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200mg once daily for six days
Number of subjects: 353

Group type: COMPARATOR
Intervention: Linezolid 600mg twice daily for 10 days
Number of subjects: 353
Study: 24055595

Group type: EXPERIMENTAL
Intervention: THC (dronabinol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22110122

Group type: EXPERIMENTAL
Intervention: DAS-steered treatment in ACPA-positive patients
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: DAS-steered treatment in ACPA-negative patients
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Initial monotherapy in ACPA-positive patients
Number of subjects: 508
Study: 20969662

Group type: EXPERIMENTAL
Intervention: Combination therapy with intradermal cross-linked hyaluronic acid and onabotulinumtoxinA
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cross-linked hyaluronic acid monotherapy
Number of subjects: 22
Study: 17624209

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) plus PCA
Number of subjects: 80

Group type: COMPARATOR
Intervention: PCA alone
Number of subjects: 80
Study: 16360446

Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor (rofecoxib 25 mg/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No COX‐2 inhibitor
Number of subjects: 96
Study: 12502178

Group type: EXPERIMENTAL
Intervention: Choline ingestion (50 mg/kg body weight)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8599618

Group type: EXPERIMENTAL
Intervention: Subclavian access (group A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Brachial access (group B)
Number of subjects: 87
Study: 2501509

Group type: EXPERIMENTAL
Intervention: TEN (Vivonex TEN)
Number of subjects: 75

Group type: COMPARATOR
Intervention: TPN (Freamine HBC 6.9% and Trophamine 6%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: TEN
Number of subjects: 75

Group type: COMPARATOR
Intervention: TPN
Number of subjects: 75
Study: 336498

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 40
Study: 31329607

Group type: COMPARATOR
Intervention: Position 0 cm (foot in full contact with footplate)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Position 8 cm (chair moved forward)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Position 6 cm
Number of subjects: 14

Group type: COMPARATOR
Intervention: Position 0 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Position 8 cm
Number of subjects: 14
Study: 29050163

Group type: EXPERIMENTAL
Intervention: Open decompression group
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Percutaneously looped thread transection group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 84
Study: 26833223

Group type: EXPERIMENTAL
Intervention: Adaptive Cogmed Working Memory Training® (CWMT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-adaptive Cogmed Working Memory Training® (CWMT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Genotyping for LMX1A‐rs4657412 TT(AA) genotype
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid analysis
Number of subjects: 120
Study: 23658479

Group type: EXPERIMENTAL
Intervention: CVT-R
Number of subjects: 470
Study: 21823552

Group type: EXPERIMENTAL
Intervention: MoxDuo 12 mg/8 mg
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: MoxDuo 6 mg/4 mg
Number of subjects: 197
Study: 19210951

Group type: EXPERIMENTAL
Intervention: Aripiprazole (2.5 to 15 mg/day, mean dose 9.0 mg/day) for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuation treatment with aripiprazole
Number of subjects: 24
Study: 16709537

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTPa-HBV plus IPV
Number of subjects: 0
Study: 14726726

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.25 mg/kg body weight
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg body weight
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylphenidate (both doses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Behavior ratings (responders vs nonresponders)
Number of subjects: 60
Study: 11739299

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg/d, n=18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Naproxen (750 mg/d, n=17)
Number of subjects: 35
Study: 10075214

Group type: EXPERIMENTAL
Intervention: Sitting position during the second stage of labor
Number of subjects: 248

Group type: COMPARATOR
Intervention: Horizontal position during the second stage of labor
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Sitting position during the second stage of labor (in group with history of episiotomy)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Horizontal position during the second stage of labor (in group with history of episiotomy)
Number of subjects: 248
Study: 7999655

Group type: EXPERIMENTAL
Intervention: 0.5% Proparacaine (P)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.03% Proparacaine (P)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.5% Proparacaine (P) after 10 minutes
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.03% Proparacaine (P) after 10 minutes
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.5% Proparacaine (P) after first instillation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.03% Proparacaine (P) after first instillation
Number of subjects: 42
Study: 2656340

Group type: EXPERIMENTAL
Intervention: Low dose (10 micrograms) of SMS 201-995
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High dose (50 micrograms) of SMS 201-995
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31288603

Group type: EXPERIMENTAL
Intervention: Young talkers (20s)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Old talkers (50s to 60s)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Listeners from Seoul (n=30) in follow-up experiment
Number of subjects: 72
Study: 29374054

Group type: EXPERIMENTAL
Intervention: Sunitinib (n = 101)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo (n = 90)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Sunitinib vs Placebo among patients with PD-L1+ tumors
Number of subjects: 610
Study: 27818309

Group type: EXPERIMENTAL
Intervention: Telephonic support for loop diuretic adherence monitoring
Number of subjects: 40

Group type: COMPARATOR
Intervention: Passive adherence monitoring alone
Number of subjects: 40
Study: 26200158

Group type: EXPERIMENTAL
Intervention: Computerized dental anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional dental anesthesia
Number of subjects: 20